Targeted Protein Degradation Therapeutics Market
完整報告名稱與涵蓋範圍
Targeted Protein Degradation Therapeutics Market Size, Share & Trends Analysis Report, By Modality (PROTACs and Heterobifunctional Degraders, Molecular Glue Degraders, Other Degradation Modalities (LYTACs, AUTACs and Degrader Conjugates)), By Therapeutic Area (Oncology, Immunology and Inflammation, Neurology, Other Therapeutic Areas), By Development Stage (Preclinical and Phase 1, Phase 2 and Phase 3, Approved and Commercial), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The targeted protein degradation therapeutics market covers medicines that eliminate disease-causing proteins by recruiting the cell's ubiquitin-proteasome or lysosomal machinery, including heterobifunctional PROTACs, molecular glue degraders and emerging modalities such as lysosome-targeting chimeras and degrader-antibody conjugates. Conventional inhibitors and immunomodulatory drugs first commercialised without a degradation rationale are excluded, while their revenues are referenced as validation of the mechanism.
The approach addresses targets that lack druggable active sites and can overcome resistance mutations that defeat inhibitors, which has attracted every major oncology company through internal programs and alliances. The pipeline has matured from preclinical chemistry to registrational trials, most notably oral estrogen receptor degraders in breast cancer and cereblon-based glues in hematologic malignancies, with immunology and neurology programs following. Commercial revenue in the forecast window is driven by approval timing, oral bioavailability advantages and positioning against existing inhibitors, while E3 ligase diversification, tissue-selective delivery and rational glue design broaden the target universe.
North America and Europe host most originators and clinical activity, and China has emerged as a significant source of degrader candidates and licensing partners. Competition combines degrader-focused biotechnology companies, large pharmaceutical partners and chemistry platform providers.
The InsightAce study includes revenue forecasts in US$ for all modality, therapeutic area, development stage and end user and regional segments across 2026-2035, segment-level trend analysis, competitive positioning assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Targeted Protein Degradation Therapeutics Market Snapshot
Chapter 4. Global Targeted Protein Degradation Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Modality Estimates & Trend Analysis
5.1. Modality & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Modality:
5.2.1. PROTACs and Heterobifunctional Degraders
5.2.2. Molecular Glue Degraders
5.2.3. Other Degradation Modalities (LYTACs, AUTACs and Degrader Conjugates)
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
6.2.1. Oncology
6.2.2. Immunology and Inflammation
6.2.3. Neurology
6.2.4. Other Therapeutic Areas
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Preclinical and Phase 1
7.2.2. Phase 2 and Phase 3
7.2.3. Approved and Commercial
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Cancer Centers
8.2.2. Specialty Pharmacies
Chapter 9. Targeted Protein Degradation Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Arvinas, Inc.
11.2. Kymera Therapeutics, Inc.
11.3. Nurix Therapeutics, Inc.
11.4. C4 Therapeutics, Inc.
11.5. Monte Rosa Therapeutics, Inc.
11.6. Pfizer Inc.
11.7. Bristol Myers Squibb
11.8. Novartis AG
11.9. Bayer AG (Vividion Therapeutics)
11.10. Roche Holding AG
11.11. AstraZeneca plc
11.12. Amgen Inc.
11.13. Cullgen Inc.
11.14. Captor Therapeutics S.A.
11.15. Haisco Pharmaceutical Group Co., Ltd.
圖表清單 List of Tables & Figures
Table 1. Global Targeted Protein Degradation Therapeutics Market Revenue Forecast by Modality, 2026-2035 (US$ Mn)
Figure 1. Global Targeted Protein Degradation Therapeutics Market Segmentation and Scope Overview
Table 2. Global Targeted Protein Degradation Therapeutics Market Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 2. Global Targeted Protein Degradation Therapeutics Market Share by Modality, 2026 & 2035
Table 3. Global Targeted Protein Degradation Therapeutics Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. Targeted Protein Degradation Pipeline by Modality, Therapeutic Area and Phase
Table 4. Global Targeted Protein Degradation Therapeutics Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Approval Timeline of Late-Stage Degraders and Revenue Inflection Points, 2026-2035
Table 5. Global Targeted Protein Degradation Therapeutics Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Targeted Protein Degradation Therapeutics Growth Opportunity Analysis
Table 6. North America Targeted Protein Degradation Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Targeted Protein Degradation Therapeutics Market Participants
Table 7. Europe Targeted Protein Degradation Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Targeted Protein Degradation Therapeutics Market
Table 8. Asia Pacific Targeted Protein Degradation Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. E3 Ligase Utilisation and Target Class Expansion Across Developers
Table 9. Strategic Developments of Leading Targeted Protein Degradation Therapeutics Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們